4GB.F Stock Analysis
4G
Uncovered
Gossamer Bio Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 178 full-time employees. The company went IPO on 2019-02-08. The firm is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its product candidates include Seralutinib (GB002), GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB5121 is selected based on its central nervous system, or CNS, penetration and kinase selectivity. GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS). GB7208 is focused on undergoing preclinical testing.